ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. Read more about SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference
ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021 Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021 Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021
ZyVersa Therapeutics' CCO, Karen A. Cashmere, Invited Speaker at Inflammasome Therapeutics Summit 2021 Read more about ZyVersa Therapeutics' CCO, Karen A. Cashmere, Invited Speaker at Inflammasome Therapeutics Summit 2021
ZyVersa Therapeutics Sponsors American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression Read more about ZyVersa Therapeutics Sponsors American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression
ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp. Read more about ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp.
ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology Read more about ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper Read more about ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper
